27 results on '"Inocencio, Timothy"'
Search Results
2. Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial.
3. Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices.
4. Health-Related Quality of Life in Patients with Metastatic Basal Cell Carcinoma Treated with Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial
5. Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab at US Oncology Clinical Practices
6. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
7. PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
8. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
9. Re: Response letter to Sanofi’s communication related to “the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States”
10. CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
11. Additional file 1 of Budget impact analysis of a digital monitoring platform for COPD
12. MM-378 Preferences Among Patients With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in the Era of B-Cell Maturation Antigen (BCMA)-Directed T-Cell–Engaging Therapies
13. Preferences Among Patients With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in the Era of B-Cell Maturation Antigen (BCMA)-Directed T-Cell–Engaging Therapies
14. Budget impact analysis of a digital monitoring platform for COPD.
15. The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China
16. The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States
17. The Economic Burden of Opioid-Related Poisoning in the United States
18. Characterization of Continued Antibacterial Therapy After Diagnosis of Hospital-Onset Clostridium difficile Infection: Implications for Antimicrobial Stewardship
19. Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan
20. P174 A model to explore the potential budget impact of a novel screening tool for the detection of subclinical rejection among kidney transplant patients
21. Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment
22. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries
23. The Economic Burden of Opioid Poisoning in the United States and Determinants of Increased Costs in Opioid Poisoning
24. Understanding the impact of settings of care and the development of chemotherapy-induced nausea and vomiting within a population of commercially insured patients.
25. Investigating rates of CINV across settings of care in Medicare: A retrospective claims-based analysis.
26. Adherence and persistence associated with an appointment-based medication synchronization program
27. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficileInfection Among Medicare Beneficiaries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.